The article provides a comprehensive analysis of drug repositioning strategies for neurodegenerative diseases, particularly focusing on neuroinflammation. Regarding the discussion on the potential timing of NSAID efficacy in Alzheimer’s disease, could you clarify how the evidence supports this pre-symptomatic window? Additionally, do the findings suggest any practical strategies for identifying at-risk populations who might benefit most from early intervention?